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Abstract
Background: Molecular profiling has uncovered genetic subtypes of glioblastoma (GBM), including tumors with IDH1
mutations that confer increase survival and improved response to standard-of-care therapies. By mapping the genetic
landscape of brain tumors in routine clinical practice, we enable rapid identification of targetable genetic alterations.
Case Presentation: A 29-year-old male presented with new onset seizures prompting neuroimaging studies, which
revealed an enhancing 5 cm intra-axial lesion involving the right parietal lobe. He underwent a subtotal resection and
pathologic examination revealed glioblastoma with mitoses, microvascular proliferation and necrosis.
Immunohistochemical (IHC) analysis showed diffuse expression of GFAP, OLIG2 and SOX2 consistent with a tumor of
glial lineage. Tumor cells were positive for IDH1(R132H) and negative for ATRX. Clinical targeted-exome sequencing
(DFBWCC Oncopanel) identified multiple functional variants including IDH1 (p.R132H), TP53 (p.Y126_splice), ATRX
(p.R1302fs*), HNF1A (p.R263H) and NF1 (p.H2592del) variants and a NAB2-STAT6 gene fusion event involving NAB2 exon
3 and STAT6 exon 18. Array comparative genomic hybridization (aCGH) further revealed a focal amplification of NAB2
and STAT6. IHC analysis demonstrated strong heterogenous STAT6 nuclear localization (in 20 % of tumor cells).
Conclusions: While NAB2:STAT6 fusions are common in solitary fibrous tumors (SFT), we report this event for the first
time in a newly diagnosed, secondary-type GBM or any other non-SFT. Our study further highlights the value of
comprehensive genomic analyses in identifying patient-specific targetable mutations and rearrangements.
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Background
Glioblastoma (GBM) is the most common, primary ma-
lignant brain tumor of adults with a median survival of
15 months despite multimodal surgical, chemo and
radiotherapy [1]. GBMs are characterized by infiltrating
tumor cells with nuclear pleomorphism, mitotic activity
and accompanying necrosis and/or endothelial prolifera-
tion. More recently, molecular profiling has uncovered
genetic subtypes among histologically indistinguishable
GBMs that confer increased survival and improved re-
sponse to standard-of-care therapies. For example,
tumors with isocitrate dehydrogenase (IDH1/2) muta-
tions show prolonged survival while tumors with
MGMT promoter methylation benefit from temozolo-
mide therapy [2, 3]. Despite inclusion of clinically rele-
vant molecular events in routine diagnostic evaluation of
brain tumors, molecular testing has largely remained
limited to a small number of genetic alterations linked
to specific tumor subtypes (e.g., 1p/19q co-deletion in
oligodendrogliomas). Such focused interrogation strat-
egies however ignore the genetic heterogeneity of cancer
and prevent screening for less common, yet clinically ac-
tionable, genetic events. Indeed, assessment of IDH1
mutation status by immunochemistry only identifies the
most common IDH1 R132H alteration, while other less
frequent, yet prognostically important IDH1/2 are not
assessed. Furthermore, other rare genetic changes that
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are potentially therapeutically actionable, such as BRAF
(p.V600E) mutations, are not routinely profiled in high-
grade gliomas [4]. Comprehensive genomic analysis of
brain tumors provides objective companion data to sup-
port and refine histologic diagnoses [5]. Furthermore, by
mapping the genetic landscape of brain tumors in rou-
tine clinical practice, we enable rapid identification of
targetable genetic alterations and support patient enroll-
ment onto molecularly stratified clinical trials.
Case presentation
A previously healthy 29-year-old male presented to an
outside hospital with a symptomatic intra-axial enhancing
right parietal brain lesion necessitating surgical manage-
ment and adjuvant temozolomide (Fig. 1a, b). Histology
showed a densely cellular infiltrating glial neoplasm com-
prised of severely atypical cells with mitoses, vascular pro-
liferation and necrosis consistent with GBM (Fig. 1c).
Immunohistochemistry demonstrates tumor cells were
Fig. 1 a Coronal T2 FLAIR highlights the intra-parenchymal location of the complex tumor resection bed and associated edema. b Axial post contrast
T1 MRI showing peripheral ring enhancement and progression from previous post-surgical imaging (right). c H&E sections showing a hypercellular
fibrillary neoplasm with morphological atypia, mitoses, and endothelial proliferation. Necrosis was also present (not shown). The tumor showed diffuse
expression of the glial markers Olig2, Sox2 and GFAP. Immunoreactivity with antibody against the R132H IDH1 mutation. ATRX immunostaining
highlighting loss within the tumor and normal retained expression in a adjacent vessel. Immunohistochemistry with the STAT6 antibody showing
strong nuclear expression in 15–20 % of tumor nuclei (inset) consistent with previous described function of NAB2-STAT6 fusion event. d Schematic
demonstrating the locations of common NAB2-STAT6 rearrangements in solitary fibrous tumor (SFTs), the presented case GBM and other STAT6
rearrangements reported in GBMs
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positive for GFAP, OLIG2, SOX2, IDH1(R132H) and a
MIB1 proliferation index of >30 % (Fig. 1c). MGMT
methylation testing revealed that the tumor was positive
for promoter methylation.
Targeted exome sequencing (OncoPanel) of 300
cancer-associated genes and 113 introns from 35 genes
for rearrangement was performed on DNA extracted
from formalin-fixed paraffin embedded tumor tissue
[6, 7]. OncoPanel revealed IDH1 (p.R132H), TP53
(p.Y126_splice), ATRX (p.R1302fs*), HNF1A (p.R263H)
and NF1 (p.H2592del) variants, several variants of un-
known significance, and a NAB2-STAT6 fusion involv-
ing exon 3 of NAB2 and exon 18 of STAT6 (Fig. 1d,
Table 1). This rearrangement has not previously been re-
ported outside the context of solitary fibrous tumors
(SFTs). In SFTs, fusion products are variable, but typically
involve exons 6/7 of NAB2 and exons 17/18 of STAT6 [8]
(Fig. 1d). Similar to the functional consequence of this fu-
sion product in SFTs, we confirmed that this novel NAB2-
STAT6 fusion detected in our GBM patient resulted in
strong STAT6 nuclear localization [9] (Santa Cruz, catalog
#sc-621), however this was present in only a subpopula-
tion of cells (Fig. 1c).
To determine whether this event might be recurrent in
gliomas, and given multiple genomic alterations detected
in this tumor closely resemble those found in adult low-
grade gliomas (ALGGs) (mutations in IDH1, TP53 and
ATRX) [10], we investigated the frequency of NAB2-
STAT6 fusions in The Cancer Genome Atlas (TCGA)
low-grade glioma database (http://cancergenome.nih.gov/).
This analysis included 50 tumors with whole genome
sequencing (WGS) and 311 tumors with whole exome
sequences (WES). Among this 361 patient cohort, we
did not detect any evidence of NAB2-STAT6 fusions,
nor fusion events involving NAB2 or STAT6 with other
fusion partners.
We next analyzed TCGA adult GBM datasets includ-
ing 42 and 164 tumors tested by WGS and RNA se-
quencing, respectively. Similar to our findings among
ALGGs, we did not detect NAB2-STAT6 fusions but
did identify two unique STAT6 fusion events STAT6-
CPM and HIPK2-STAT6 and each co-amplified with
oncogenes CDK4 and MDM2 in the amplicon on
chromosome 12q13-15. These observations suggest that
STAT6 fusions occur at a low frequency but may be re-
current with other 12q13-15 amplification events.
Given this finding, we performed genome wide array
comparative genomic hybridization (aCGH), or copy
number analysis, of our case study GBM and also iden-
tified co-amplification of NAB2, STAT6 and CDK4 in-
volving a 12q3-14 amplicon of 0.6 Mb (Table 2).
Conclusions
Incorporating molecular analyses into current diagnostic
pipelines for GBM patients may provide an avenue for
identifying novel aberrations or events that have been
previously reported in other tumor types [7]. One study
reported that such a genome wide screening strategy can
in fact yield candidate actionable genetic alterations in
every case analysed [6]. Here we demonstrate that
targeted-exome sequencing of a GBM revealed a NAB2-
STAT6 fusion, which is a known oncogenic driver in
SFTs but has not been reported in other cancers. In
SFTs, the novel fusion product results in nuclear trans-
location of the STAT6 transcriptional activating domain
and activation of the early growth response (EGR1)
pathway leading to tumorigensis [8, 11]. The strong nu-
clear STAT6 staining in a subpopulation of GBM cells
parallels what is found in SFTs, suggesting a similar
mechanism of action. Given its high frequency in SFTs,
the NAB2-STAT6 fusion has raised interest as both a
diagnostic and potentially druggable therapeutic target
[12]. Although the frequency of this event has not been
fully explored, our results from querying TCGA ALGG
and GBM datasets demonstrates that specific NAB2-
STAT6 fusion events are rare in gliomas but that STAT6
fusions are recurrent events with several partners in
adult GBM. Despite the low recurrence frequency, this
fusion supports repurposing drugs developed against the
NAB2-STAT6 or the EGR pathway in SFTs as a potential
alternative or adjuvant therapy for patients with genetic-
ally similar gliomas.
Interestingly, similar to other STAT6 rearrangement
events in GBMs, we noted CDK4 amplification in this
patient. Chromosome 12 is frequently subject to a storm
of amplification/rearrangement events in GBMs, includ-
ing CDK4, MDM2, and HMGA2 amplifications as well
as other regions (including KRAS). These events suggest
a more complex rearrangement involving much of the
chromosome and are reminiscent of ring chromosomes
found in dedifferentiated liposarcomas [13–15]. Given
the genetic proximity of CDK4 and MDM2 to STAT6
and NAB2 in the chromosomal region 12q13-15, the
fusion product may represent a consequence of this
Table 1 Mutations identified in GBM patient by targeted exome
sequencing (OncoPanel)
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more complex rearrangement. Understanding the pre-
cise functional consequences of this molecular alter-
ation in glioma biology will be important to guiding
future therapies of similar cases [13]. As genome wide
sequencing strategies become more widely available in
the clinical setting, infrequent mutations and/or rare
fusion events may collectively represent a brain tumor
patient population that can be managed with targeted
therapies approved for use in other tumor types. This
strategy may pave the way for improving outcomes in a
small subset of GBM patients.
Consent
Written informed consent was obtained for 10–417 and
11–104 (OncoPanel) from the patient for sequencing
analysis, publication of this report and accompanying
images.
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Table 2 aCGH copy number alterations identified in GBM
patient
Gene/Region Chromosome Band Copy Number Change Nucleotides
(GRCh37//hg19)
MYCL1 1p34.2 – –
CDKN2C 1p33 – –
PIK3C2B 1q32.1 –
MDM4 1q32.1 – –
AKT3 1q44 –
MYCN 2p24.3 – –
PIK3CA 3q26.32 –
SOX2 3q26.33 – –
FGFR3 4p16.3 –
PDGFRA 4q12 550 kb focal gain chr4:55,072,465
–55,622,596
TERT 5p15.33 –
MYB 6q23.3 – –
PARK2 6q26 –
QKI 6q26 – –
EGFR 7p11.2 –
EGFRvIII 7p11.2 – –
CDK6 7q21.2 –
MET 7q31.2 – –
BRAF 7q34 –
FGFR1 8p11 23-p11.22 – –
MYBL1 8q13.1 –
MYC 8q24.21 – –




NTRK2 9q21.32-q21.33 1.3 Mb focal gain chr9:86,840,129
–88,134,100
















NAB2 12q13.3 37 kb amplification chr12:57,484,461
–57,521,151
STAT6 12q13.3 37 kb amplification chr12:57,484,461
–57,521,151
CDK4 12q14.1 131 kb amplification chr12:58,034,214
–58,165,540












Table 2 aCGH copy number alterations identified in GBM
patient (Continued)
NF1 17q11.2 –








1p- n/a – –
4p- n/a –
Monosomy 6 n/a –
6q- n/a –
















Monosomy 22 n/a Detected chr22:16,133,474
–51,219,009
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